Search Results
Search for other papers by M C F Mulders in
Google Scholar
PubMed
Search for other papers by Q G de Lussanet de la Sablonière in
Google Scholar
PubMed
Search for other papers by M L F van Velthuysen in
Google Scholar
PubMed
Search for other papers by E M Roes in
Google Scholar
PubMed
Search for other papers by J Hofland in
Google Scholar
PubMed
Search for other papers by W W de Herder in
Google Scholar
PubMed
Introduction Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that predominantly arise from neuroendocrine cells of the embryonic gut and are subdivided into foregut, midgut and hindgut NETs ( Hofland et al. 2020 ). NET
Search for other papers by Alexa Childs in
Google Scholar
PubMed
Search for other papers by Amy Kirkwood in
Google Scholar
PubMed
Search for other papers by Julien Edeline in
Google Scholar
PubMed
Search for other papers by Tu Vinh Luong in
Google Scholar
PubMed
Search for other papers by Jennifer Watkins in
Google Scholar
PubMed
Search for other papers by Angela Lamarca in
Google Scholar
PubMed
Search for other papers by Doraid Alrifai in
Google Scholar
PubMed
Search for other papers by Phyllis Nsiah-Sarbeng in
Google Scholar
PubMed
Search for other papers by Roopinder Gillmore in
Google Scholar
PubMed
Search for other papers by Astrid Mayer in
Google Scholar
PubMed
UCL Cancer Institute, UCL, London, UK
Search for other papers by Christina Thirlwell in
Google Scholar
PubMed
Search for other papers by Debashis Sarker in
Google Scholar
PubMed
Search for other papers by Juan W Valle in
Google Scholar
PubMed
UCL Cancer Institute, UCL, London, UK
Search for other papers by Tim Meyer in
Google Scholar
PubMed
count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms . British Journal of Cancer 108 1838 – 1845 . ( doi:10.1038/bjc.2013.156 ) Khan MS Kirkwood AA Tsigani T Lowe H Goldstein R Hartley JA
ENETS Center of Excellence, Department of Endocrinology, University Hospital Basel, Basel, Switzerland
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Julie Refardt in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Tessa Brabander in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Gaston J H Franssen in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) consist of a diverse group of tumors arising from neuroendocrine cells and are mainly localized in the intestine, pancreas and lung ( Hofland et al. 2020 ). Classification of NENs is based on
Search for other papers by J Hadoux in
Google Scholar
PubMed
Search for other papers by D Malka in
Google Scholar
PubMed
Search for other papers by D Planchard in
Google Scholar
PubMed
Search for other papers by J Y Scoazec in
Google Scholar
PubMed
Search for other papers by C Caramella in
Google Scholar
PubMed
Search for other papers by J Guigay in
Google Scholar
PubMed
Search for other papers by V Boige in
Google Scholar
PubMed
Search for other papers by S Leboulleux in
Google Scholar
PubMed
Search for other papers by P Burtin in
Google Scholar
PubMed
Search for other papers by A Berdelou in
Google Scholar
PubMed
Search for other papers by Y Loriot in
Google Scholar
PubMed
Search for other papers by P Duvillard in
Google Scholar
PubMed
Search for other papers by C N Chougnet in
Google Scholar
PubMed
Search for other papers by D Déandréis in
Google Scholar
PubMed
Search for other papers by M Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by I Borget in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by M Ducreux in
Google Scholar
PubMed
Search for other papers by E Baudin in
Google Scholar
PubMed
, temozolomide chemotherapy combined with capecitabine and/or bevacizumab was also proposed as an alternative for patients with neuroendocrine neoplasms and high proliferative index ( Welin et al . 2011 ). However, the applicability of this regimen in patients
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Martin O Weickert in
Google Scholar
PubMed
Search for other papers by Harpal S Randeva in
Google Scholar
PubMed
Division of Pathophysiology, National and Kapodistrian University of Athens Medical School, Athens, Greece
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Ashley Grossman in
Google Scholar
PubMed
Sulentic P Xu JM Grossman AB 2017 Thymic neuroendocrine neoplasms: biological behaviour and therapy . Neuroendocrinology [in press]. ( doi:10.1159/000472255 ) Johnson BE Damodaran A Rushin J Gross A Le PT Chen HC
Search for other papers by S M Sadowski in
Google Scholar
PubMed
Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by C R C Pieterman in
Google Scholar
PubMed
Search for other papers by N D Perrier in
Google Scholar
PubMed
Search for other papers by F Triponez in
Google Scholar
PubMed
Search for other papers by G D Valk in
Google Scholar
PubMed
. ( https://doi.org/10.1210/jc.2014-3659 ) Grolmusz VK Kovesdi A Borks K Igaz P Patocs A 2018 Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms . European Journal of Endocrinology 179 219 – 228
Department of Clinical Sciences, Lund University, Lund, Sweden
Department of General and Endocrine Surgery, OLV Clinic Aalst, Aalst, Belgium
Search for other papers by Klaas Van Den Heede in
Google Scholar
PubMed
Department of Endocrine Surgery, Hammersmith Hospital, London, UK
Search for other papers by Swathikan Chidambaram in
Google Scholar
PubMed
Department of Head and Skin, University Hospital Ghent, Ghent, Belgium
Department of General Surgery, AZ Damiaan, Ostend, Belgium
Search for other papers by Sam Van Slycke in
Google Scholar
PubMed
Global Health Institute, University of Antwerp, Wilrijk, Belgium
Search for other papers by Nele Brusselaers in
Google Scholar
PubMed
Department of Oncology and Pathology, Lund University, Lund, Sweden
Search for other papers by Carl Fredrik Warfvinge in
Google Scholar
PubMed
Department of Surgery, Ystad Hospital, Ystad, Sweden
Search for other papers by Håkan Ohlsson in
Google Scholar
PubMed
Search for other papers by Rita Gustafsson in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Lund, Sweden
Search for other papers by Erik Nordenström in
Google Scholar
PubMed
Department of Clinical Sciences, Lund University, Lund, Sweden
Search for other papers by Martin Almquist in
Google Scholar
PubMed
patients with small bowel neuroendocrine neoplasms in the Netherlands . World Journal of Surgery 45 2482 – 2491 . ( https://doi.org/10.1007/s00268-021-06119-y ) Landerholm K Zar N Andersson RE Falkmer SE Jarhult J 2011 Survival and prognostic
Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for other papers by Atsuko Kasajima in
Google Scholar
PubMed
Search for other papers by Yuichi Ishikawa in
Google Scholar
PubMed
Search for other papers by Ayaka Iwata in
Google Scholar
PubMed
Search for other papers by Katja Steiger in
Google Scholar
PubMed
National Hospital Organization, Sendai Medical Center, Sendai, Japan
Search for other papers by Naomi Oka in
Google Scholar
PubMed
Search for other papers by Hirotaka Ishida in
Google Scholar
PubMed
Search for other papers by Akira Sakurada in
Google Scholar
PubMed
Search for other papers by Hiroyoshi Suzuki in
Google Scholar
PubMed
Search for other papers by Toru Kameya in
Google Scholar
PubMed
Search for other papers by Björn Konukiewitz in
Google Scholar
PubMed
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
Search for other papers by Yoshinori Okada in
Google Scholar
PubMed
Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
Member of the German Cancer Consortium (DKTK)
Search for other papers by Wilko Weichert in
Google Scholar
PubMed
likely to metastasize and have a worse prognosis, these two neoplasms share the same phenotype and genotype ( Simbolo et al . 2017 ). In contrast to carcinoids, SCLC and LCNEC are high-grade neuroendocrine carcinomas (NEC) ( Travis et al . 2015
Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Search for other papers by Josh Mailman in
Google Scholar
PubMed
Search for other papers by Michael W Rabow in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by Sarah Creed in
Google Scholar
PubMed
Search for other papers by Hagen F Kennecke in
Google Scholar
PubMed
Search for other papers by Janice Pasieka in
Google Scholar
PubMed
Search for other papers by Jennifer Zuar in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
Search for other papers by Lauren Fishbein in
Google Scholar
PubMed
relation to benefits to their patients. Summary Patients with neuroendocrine neoplasms have unique disease-related symptoms that impact palliative care needs during routine disease management and at the end of life. There are special considerations
Search for other papers by M Cives in
Google Scholar
PubMed
Search for other papers by P L Kunz in
Google Scholar
PubMed
Search for other papers by B Morse in
Google Scholar
PubMed
Search for other papers by D Coppola in
Google Scholar
PubMed
Search for other papers by M J Schell in
Google Scholar
PubMed
Search for other papers by T Campos in
Google Scholar
PubMed
Search for other papers by P T Nguyen in
Google Scholar
PubMed
Search for other papers by P Nandoskar in
Google Scholar
PubMed
Search for other papers by V Khandelwal in
Google Scholar
PubMed
Search for other papers by J R Strosberg in
Google Scholar
PubMed
Introduction Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms characterized by a relatively indolent rate of growth and a propensity to produce and secrete a variety of hormones that give rise to diverse clinical syndromes